Background: Hippo pathway effectors YAP and TAZ are transcriptional coactivators that regulate cellular proliferation and tumorigenesis. Results: YAP negatively regulates TAZ abundance in a GSK-3-dependent manner. Conclusion: Changes in YAP abundance results in compensatory changes in TAZ to maintain Hippo signaling homeostasis. Significance: This initial reporting of a direct relationship between YAP and TAZ abundances has profound implications for understanding their biological functions.
YAP (yes-associated protein) 4 and TAZ (transcriptional coactivator with PDZ-binding motif) are effectors of Hippo signaling in mammalian cells (1, 2) , which promote growth and survival via the transcription of genes involved in cell growth including connective tissue growth factor (3, 4) , amphiregulin (5, 6) , survivin (7) , and cyclin A (8) . This is demonstrated by numerous studies in vitro, using cell lines whereby knockdown or overexpression of YAP or TAZ results in changes in cellular proliferation, and in some studies apoptotic resistance (8 -12) . Moreover, studies in which the expression of YAP and/or TAZ was dysregulated in tissues including liver, skin, intestine, and neural tube have confirmed a role for these effectors in proliferative processes in vivo (7, (13) (14) (15) (16) .
Because of their pro-proliferative and anti-apoptotic properties, it is not surprising that YAP and TAZ function as oncogenes. Numerous studies have revealed that YAP and TAZ induce cellular traits characteristic of tumorigenic transformation including growth factor-independent proliferation, anchorage-independent growth, and triggering of epithelialmesenchymal transition (17, 18) . Dysregulation of YAP/TAZ expression has also been reported in most solid cancer types including ovarian, brain, liver, lung, and breast cancers (19 -22) , and targeting the Hippo pathway to alter YAP/TAZ activity has shown promise as a novel strategy for cancer treatment (for a comprehensive review see Ref. 23 ). Interestingly, a pro-apoptotic role for YAP has also been reported, mediated by association with p73 in response to apoptotic stimuli such as DNA damage in cell lines (24 -27) . In support of this, YAP has been reported as a tumor suppressor in human breast and colorectal cancers (28, 29) .
Given the significant role of these transcriptional coactivators in growth and tumorigenesis, the expression and nuclear localization of YAP and TAZ is necessarily tightly regulated. The Hippo pathway negatively regulates YAP/TAZ abundance as well as their nuclear localization. Activated by upstream signals such as cell-cell contact, Mst1/2 phosphorylates and thereby activates LATS 1/2 kinase(s) resulting in the phosphorylation of YAP and TAZ, leading to their cytoplasmic sequestration and inhibition of target gene transcription (1, 7, 25, 30) . More recently, it was shown that an additional LATS 1/2 phosphorylation site in YAP and TAZ provides the priming signal for subsequent phosphorylation by casein kinase 1 ␦⑀ (CK1␦/⑀) (31, 32) . Phosphorylation on this phosphodegron site promotes ␤-TrCP binding and recruitment of the SCF ␤-TrCP E3 ligase complex for subsequent ubiquitination and proteasomal degradation.
Similarly, glycogen synthase kinase-3␣ and ␤ (GSK-3␣/␤) has been shown to promote TAZ degradation by phosphorylating TAZ on two N-terminal phosphodegron sites in response to PI3K/Akt signaling (33) . Interestingly, this phosphodegron is not conserved in YAP. An alternate mechanism proposes that GSK-3 does not directly phosphorylate TAZ, but rather GSK-3 phosphorylates ␤-catenin, which interacts with Axin1, TAZ and ␤-TrCP to form the ␤-catenin destruction complex leading to TAZ degradation (34, 35) .
The discordance between these studies may be explained by species and cell-specific differences as one utilized mouse NIH3T3 fibroblasts (33) whereas the other used human cells, namely MCF10A-MII pre-malignant breast cancer and HEK293 cells (34) . This is supported by the observation that NIH3T3 and HeLa cells exhibit significant differences in the phosphorylation of N-and C-terminal phosphodegrons, with respect to TAZ degradation (33) .
While there is an abundance of evidence that shows expression of both YAP and TAZ can have significant effects on a multitude of cell types a direct relationship, if any, between the two proteins has yet to be demonstrated. To address this knowledge gap in Hippo signaling we sought to determine whether the abundance of YAP and TAZ is linked. Surprisingly, modulating YAP abundance either by overexpression or gene knockdown using shRNA resulted in a concomitant decrease or increase in TAZ abundance, respectively. Interestingly, this inverse relationship was uni-directional and only observed upon modulation of YAP levels and not following changes to TAZ abundance. This relationship has profound implications for Hippo signaling and cancer.
Experimental Procedures
Antibodies and Chemicals-Anti-YAP (4912) for Western blotting, Anti-TAZ (V386) (4883) for Western blotting, Anti-GSK-3␣ (4337), Anti-GSK-3␤ (12456), Anti-Phospho-GSK-3␣/␤ (Ser-21/9) (8566), MG-132 (2194), Anti-GAPDH (D16H11) XP (5174), and Leptomycin B (LMB, 9676) were purchased from Cell Signaling Technology (Genesearch, Arundel, QLD). Anti-YAP for immunofluorescence has been described previously (25) . Anti-TAZ (560235) for immunofluorescence was purchased from BD-Biosciences (Zuellig Pharma, Singapore). Alexa-488 Donkey-Anti-Mouse (A21202) and Alexa-488 Goat-Anti-Rabbit (A11034) were purchased from Thermo Fisher Scientific. Anti-␤-actin (A1978), 4-hydroxytamoxifen (4HT, H7904), cycloheximide (CHX, C7698), DMSO (D8418), Calpain inhibitor I (LLnL) (A6185), and 17-(Allylamino)-17demethoxy-geldanamycin (17-AAG, A8476) were purchased from Sigma-Aldrich (Castle Hill, NSW). Anti-LATS 1 (A300-477A), and anti-LATS 2 (A300-479A) were purchased from Bethyl Laboratories Inc (VWR International, Muarrie, QLD). CK1 inhibitor IC261 (#400090) and GSK-3 inhibitor IX (BIO, 361550) were purchased from Merck Millipore (Kilsyth, VIC). Q-Val-Asp (non-omethylated)-OPh pan caspase inhibitor (Q-VD) (IMI-2309) was purchased from Imgenex (Jomar Bioscience, Welland, SA).
Plasmids and cDNAs-Marius Sudol (National University of Singapore) generously provided plasmids containing cDNAs for hYAP1-2␣ and hYAP1-1␤ (36) and mouse YAP (mYAP, NCBI NM_009534.3). mYAP mutants WW1*/WW2* (W184A, P187A, W243A, and P246A), SH3* (P272A), and TEAD* (S79A) (see Fig. 2C ) were generated using site-directed mutagenesis. Truncation mutants were generated by PCR using primers: 5Ј-GTAGGATCCATGGAGCCCGCGCAACA and 5Ј-GTGTCTAGACTATGGGCTCTGGGGAGCCAA for ⌬CT, 5Ј-GTGTCTAGACTATAACCACGTGAGAAATGG-GCTCTGGGGAGCCAAGGGT for ⌬TAD, and 5Ј-GTGTCT-AGACTAGCTTTCTTTATCTAGCTTGGTG for ⌬PDZ (see Fig. 2C ). hYAP1-1␣ was generated by overlapping PCR of hYAP1-2␣ and hYAP1-1␤ using primers: 5Ј-GTAAGATCT-GCCACCATGGATCCCGGGCAGCA with 5Ј-CTGCCGAA-GCAGTTCTTGCTGTTTCAG and 5Ј-CTGAAACAGCAA-GAACTGCTTCGGCAG with 5Ј-GTGTCTAGACTATAAC-CATGTAAGAAAGCT. Mouse TAZ (mTAZ) (NCBI NM_ 133784.3) was amplified from cDNA prepared from mRNA isolated from a murine liver progenitor cell (LPC) line and cloned into pCR-TOPO2.1 (Life Technologies, Mulgrave, VIC). All constructs were then subcloned into the 4HT-inducible lentiviral expression vector, pF-5xUAS-MCS-W-SV40puro (37, 38 and see Fig. 1D ).
Stable gene knockdown was performed using lentiviral shRNAs. Control (Con) (SHC202), YAP (KD) (TRCN0000238432), mouse TAZ (KD1) (TRCN0000095951), mouse TAZ (KD2) (TRCN0000095953), LATS (KD1) (TRCN0000274539), LATS (KD2) (TRCN0000274541), human TAZ (KD1) (TRCN 0000319149), and human TAZ (KD2) (TRCN0000370007) shRNA MISSION plasmids were purchased from Sigma.
Cell Culture-MEFs, NIH3T3 and HEK293T cells were provided by David Vaux (Walter and Eliza Hall Institute (WEHI, VIC). HeLa and D645 cells were obtained from David Huang (WEHI) and John Silke (WEHI), respectively. MCF-7 cells were provided by Louise Wedlock (UWA). Cells were maintained in DMEM (Life Technologies, 11885) supplemented with 10%
(v/v) fetal bovine serum (FBS), 50 units/ml penicillin G/50 g/ml streptomycin, 2 mM L-glutamine in a humidified atmosphere of 10% CO 2 at 37°C. EpH4-Ev (EpH4) cells were purchased from ATCC (ATCC CRL-3063) and were maintained in DMEM (Biowest, L0102) supplemented with 10% (v/v) FBS, 100 units/ml penicillin G/100 g/ml streptomycin in a humidified atmosphere of 5% CO 2 at 37°C.
Actin-EGFP LPCs were generated by GCY and cultured in Williams' Medium E (Sigma, W4125-10X1L) supplemented with 5% (v/v) FBS 2.5 g/ml amphotericin B, 80 units/ml penicillin G/675 g/ml streptomycin, 2 mM L-glutamine, 10 g/ml Humulin R U-100 (UWA Pharmacy, Nedlands, WA), 30 ng/ml insulin-like growth factor II (ProSpec Ness-Ziona, Israel #CYT-265), and 20 ng/ml epidermal growth factor (BD Biosciences, North Ryde, NSW 354001) in a humidified atmosphere of 5% CO 2 at 37°C.
The generation of lentiviruses and 4HT-inducible cell lines have been described before (37, 39) . Gene expression in target cells was induced by the addition of 100 nM 4HT. Stable knockdown cells were generated by infection with shRNA-bearing lentiviruses and selection with puromycin.
Generation of YAP CRISPR-Cas9 Cell Line-WT EpH4 cells were transfected with the GeneArt CRISPR Nuclease vector with orange fluorescent protein reporter (Thermo Fisher Scientific, A21174) containing mYAP-targeting guide RNA sequence 5Ј-GCCCAAGTCCCACTCGCGAC using Lipofect-amine2000 (Thermo Fisher Scientific) according to the manufacturer's instructions. Three days post-transfection single cells expressing OFP were sorted into 96-well plates, subsequently expanded, and individually screened for loss of YAP protein expression by Western blot.
Cell Lysis and Immunoblotting-Cell lysates were prepared as described before (40) . Lysates (50 g) were separated by SDS-PAGE and transferred to Hybond C nitrocellulose membrane (GE, Castle Hill, NSW). Membranes were immunoblotted with antibodies and detected with chemiluminescence essentially as described before (39) except Tris-buffered saline containing 0.1% Tween-20 (v/v) was used for washing membranes.
Immunofluorescent Staining-Cells were grown on glass coverslips and fixed for 10 min with 4% paraformaldehyde in PBS. TAZ immunofluorescence staining was performed as described previously (20) using Anti-TAZ (1/200) and Alexa-488 Anti-mouse secondary (1/200), with block solution and diluents prepared using bovine serum albumin (BSA). YAP immunofluorescence staining was performed using a modified protocol; cells were first permeabilized using PBS containing 0.1% (v/v) Triton X-100 (PBST) for 15 min at room temperature before washing three times with PBS, then another three times with PBS containing 0.5% (w/v) BSA. Cells were blocked with 5% (w/v) BSA in PBS for 30 min at 37°C, washed three times with PBST before incubation in Anti-YAP diluted (1/5000) in PBST containing 1% (w/v) BSA overnight at 4°C. After three washes with PBST cells were incubated with Alexa-488 Antirabbit secondary (1/300) diluted in PBS containing 0.5% (w/v) BSA for 1 h at room temperature. After final washes coverslips were mounted onto slides using ProLong Diamond Antifade mountant with DAPI (ThermoFisher Scientific) and allowed to cure overnight. Stained cells were visualized using the EVOS FL cell imaging system.
Cell Proliferation Assay-Cells were seeded in 96-well plates at 1 ϫ 10 4 cells/ml and cell confluency as a percentage of total area was measured twice daily using a CellaVista (Roche).
Quantitative Real-time PCR (qPCR)-The transcript abundance of YAP was determined using primers 5Ј-CAGGAATT-ATTTCGGCAGGA and 5Ј-CATCCTGCTCCAGTGTAGGC with Roche Universal Probe Library (UPL) probe 71. TAZ abundance was determined using primers 5Ј-GTTCCAGCTCG-TCAGTTCG and 5Ј-TGCGTGACGTGGATGACT with UPL probe 70. TAF4A was used to normalize gene expression for YAP and TAZ using primers 5Ј-CCACAGCAGATCCAAC-TGAA and 5Ј-GGTAACACGGTGGGTTTCAC with UPL probe 71. qPCR amplification was performed using the Light-Cycler 480 System (Roche) using Roche LightCycler 480 Probes Master (04707494001) with 0.2 M of each primer, and 0.15 M UPL probe and the following cycling conditions: 95°C for 10 min, then 55 cycles of 95°C for 10 s followed by 59°C for 30 s, and finally 40°C for 30 s.
Crystal Violet Staining of Cells-Cells in 60-mm culture dishes were washed once with PBS before being fixed with PBS containing 1% (v/v) glutaraldehyde (Sigma, G6257) for 10 min at room temperature. Cells were washed twice with PBS before being stained with a 0.1% (w/v) crystal violet (Sigma, C3886) solution for 20 min at room temperature. Cells were washed three times with water and dried overnight.
Results
To determine whether a relationship exists between the abundance of YAP and TAZ, initially YAP expression was abolished in murine cells using shRNA. Consistent with reports in other cell lines (10, 41) , ablation of YAP in LPCs decreased cellular proliferation ( Fig. 1A) in cells with undetectable YAP expression as determined by Western blot (Fig. 1B) . Surprisingly, TAZ abundance was significantly increased in the YAP knockdown (KD) cells compared with uninfected wild-type (WT) cells, or those infected with the non-targeting control (Con) shRNA ( Fig. 1B) . To ascertain whether the increased TAZ abundance following YAP knockdown was specific to LPCs, YAP was ablated in NIH3T3 cells and immortalized MEFs with shRNA. Consistent with the LPC data, YAP was effectively depleted in both KD cell lines, and TAZ abundance was modestly, but consistently, increased in NIH3T3 KD and MEF KD cells compared with Con and WT cells, respectively ( Fig. 1B) .
Increased TAZ abundance upon shRNA-mediated YAP depletion was confirmed using CRISPR-Cas9 gene disruption to generate a YAP null clone of EpH4 cells (Fig. 1C) . YAP knock-out significantly increased TAZ abundance by Western blot, and this increase was also detectable by immunofluorescent staining for TAZ in these cells compared with WT ( Fig. 1C ).
To test whether increased YAP expression can reduce the abundance of TAZ, and also to eliminate the possibility that increased TAZ in the YAP depleted cells resulted from selection of cells with inherently higher TAZ expression, a shortterm, 4HT-inducible expression system was utilized (Fig. 1D ).
As expected, treatment of parental NIH3T3 cells (NIH) with 4HT for 24 h had no effect on YAP or TAZ abundance, whereas a significant increase in YAP was observed within 8 h of 4HT addition in YAP-inducible NIH3T3 cells (NIH iYAP) ( Fig. 1E ). Noticeably, this was accompanied by a significant decrease in TAZ abundance after 16 h of 4HT treatment (Fig. 1E ). The finding that YAP induction decreases TAZ abundance was subsequently confirmed in YAP-inducible MEFs and LPCs (Fig.  1E) . Importantly, the effect on TAZ was specific to YAP since treatment of parental NIH3T3 cells with 4HT alone did not affect TAZ abundance.
To determine whether the decrease in TAZ abundance was the result of altered TAZ mRNA expression qPCR analysis was performed. Treatment of YAP-inducible NIH3T3 cells for 48 h with 4HT resulted in a 38-fold increase in YAP mRNA (p Ͻ 0.01) ( Fig. 1F) , which was consistent with changes observed at the protein level ( Fig. 1E ). Interestingly, TAZ mRNA expression was not significantly altered following 48 h of 4HT treat-FIGURE 1. YAP inversely regulates TAZ abundance in mammalian cells. A, WT liver progenitor cells (LPCs) were stably infected with lentivirus bearing control (Con) or YAP-specific (KD) shRNAs. Cell confluency of stable cell lines was measured using a CellaVista. Data are presented as mean Ϯ S.E. (n ϭ 3). B, WT LPCs, NIH3T3 cells and MEFs were stably infected with lentivirus bearing control (Con) or YAP-specific (KD) shRNAs. C, WT EpH4 cells were transfected with mYAP-targeting CRISPR-Cas9 plasmid and a YAP-null clone (YAP CRISPR) was selected and immunostained for YAP and TAZ. D, schematic representation of the 4HT inducible lentiviral expression system. Constitutive expression of the GEV16 transcription factor (GEV16 TF) is driven by the ubiquitin promoter. Following addition of 4HT, GEV16 TF translocates to the nucleus where its GAL4-DNA binding domain directs binding to GAL4 upstream activating sequences (5xUAS) to drive expression of YAP or TAZ gene expression. E, WT NIH3T3 cells (NIH), and YAP-inducible (iYAP) NIH cells, MEFs and LPCs were treated with or without 4HT for 24 h or as indicated. F, NIH iYAP cells were treated with or without 4HT for 48 h. Total RNA was harvested and qPCR analysis was performed to determine relative YAP and TAZ mRNA expression. Data are presented as mean Ϯ S.E. (n ϭ 3), with expression in non-4HT-treated cells arbitrarily set to 1.0. Statistical analysis was performed using a one-way ANOVA with Tukey's multiple comparison test, **, p Ͻ 0.01. G, WT LPCs were stably infected with lentivirus bearing control (Con) or mouse TAZ-specific (KD1 and KD2) shRNAs. TAZ-inducible NIH3T3 cells (NIH iTAZ) were treated with 4HT for 24 h to induce TAZ expression. Cell lysates were separated by SDS-PAGE, transferred to membrane and immunoblotted for YAP, TAZ, and the loading control ␤-actin or GAPDH, as indicated. Size markers are shown in kilodaltons. NOVEMBER 13, 2015 • VOLUME 290 • NUMBER 46 JOURNAL OF BIOLOGICAL CHEMISTRY 27931 ment (Fig. 1F ). Collectively these results show that YAP posttranscriptionally modulates TAZ abundance and this is not due to cell selection during continuous passage but is rather a direct consequence of YAP abundance.
YAP Regulates TAZ Protein Accumulation
Because YAP and TAZ are similarly regulated within cells (1, 30 -32) , it was hypothesized that TAZ might similarly regulate YAP abundance. To investigate this, LPCs were infected with lentivirus bearing TAZ-specific shRNA. Despite a significant reduction in TAZ abundance in both TAZ shRNA infected LPC lines (KD1 or KD2), YAP abundance was unchanged (Fig. 1G ). Next, to determine whether TAZ overexpression could alter YAP abundance, TAZ-inducible NIH3T3 cells (NIH iTAZ) were generated. Despite a significant increase in TAZ 24 h post 4HT treatment, no change in YAP abundance was observed (Fig. 1G ). From these experiments it was concluded that the level of TAZ protein does not affect YAP abundance. Furthermore this indicates that in addition to the regulatory mechanisms shared by YAP and TAZ, the abundance of TAZ is fur-ther modulated by a direct effect of YAP, but not vice versa. This is, at least in part, a possible consequence of differences in protein stability.
To confirm whether differences exist between YAP and TAZ protein stability, NIH3T3 cells were treated with CHX to block protein synthesis. CHX treatment led to a faster decrease in TAZ abundance compared with YAP ( Fig. 2A) . Conversely, inhibition of the proteasome by treatment with MG-132, led to a rapid accumulation of TAZ but not YAP indicating TAZ is more rapidly turned over and significantly less stable than YAP ( Fig. 2A) .
To discern the method of TAZ depletion following YAP induction YAP-inducible cells were independently treated with MG-132 to block proteasomal degradation, NH 4 Cl to disrupt lysosomal-facilitated degradation by increasing the pH of intracellular vesicles, or LLnL to block the calcium-dependent neutral cysteine protease calpain I. Treatment with MG-132 protected TAZ from YAP-induced depletion in YAP-inducible cells whereas NH 4 Cl and LLnL failed to prevent TAZ loss (Fig.  2B) . Similarly, treating cells with LMB to inhibit nuclear export, completely blocked YAP-induced TAZ degradation after 24 h of 4HT treatment (Fig. 2B) . These results indicate that upon YAP induction, TAZ is proteasomally degraded within the cytoplasm, which is consistent with the established mechanism of TAZ degradation (32, 33, 42) .
To determine which YAP domain/s are required to induce TAZ degradation several mYAP deletion constructs were generated and the ability of these mutants to promote TAZ degradation after 24 h of induction was assessed. Deletion of YAP's transcriptional activation domain (TAD) and PDZ-binding motif (construct ⌬CT) totally abolished YAP-mediated TAZ degradation compared with WT YAP (Fig. 2C) , and deletion of either of these domains (⌬TAD or ⌬PDZ) revealed that both are necessary to induce TAZ degradation. Mutation of YAP's WW domains (WW1*/WW2*) or SH3-binding domain (SH3*) did not affect YAP's ability to degrade TAZ whereas disruption of YAP's TEAD-binding domain (TEAD*) with the point mutation, S79A, partially blocked TAZ degradation compared with WT YAP (Fig. 2C ). Together, these data suggest that the PDZbinding and transcription activation domains are necessary to promote TAZ degradation and that this is at least partly mediated by DNA-binding TEAD factors.
Since phosphorylation of YAP and TAZ by LATS 1/2 kinase(s) is necessary for CK1-mediated degradation (32), we hypothesized that LATS 1/2 may mediate YAP-induced TAZ degradation. The heat shock protein 90 (Hsp90) inhibitor 17-AAG was shown to deplete LATS 1 and 2 leading to a decrease in YAP phosphorylation in A549 and MCF10A cells (43) . Treatment of NIH iYAP cells with 17-AAG blocked the increase of LATS 1 induced by YAP overexpression, though it only partially blocked the increase of LATS 2 (Fig. 3A) . Strikingly, 17-AAG treatment completely prevented YAP-induced TAZ degradation (Fig. 3A) , indicating that a Hsp90 substrate, possibly LATS kinase, mediates YAP-induced TAZ degradation. To address this, shRNAs were utilized to ablate LATS 1/2 abundance. However, partial knockdown of LATS 1 and 2 failed to prevent YAP-induced TAZ degradation (Fig. 3B ). While not conclusive, this suggests that LATS kinases are possibly not involved.
Since the requirement of the LATS kinases for YAP-induced TAZ degradation was inconclusive, the role of other known mediators of TAZ degradation, CK1␦/⑀ and GSK-3␣/␤, were investigated. Treatment of NIH iYAP cells with the CK1␦/⑀ inhibitor IC261 in combination with 4HT was unable to prevent YAP-induced TAZ degradation (Fig. 3C ), suggesting that the reported LATS 1/2-CK1␦/⑀ mechanism of TAZ degradation is not involved.
Next we investigated the involvement of GSK-3␣/␤ in YAPinduced TAZ depletion. Strikingly, treatment with the GSK-3 inhibitor BIO completely blocked YAP-mediated TAZ degradation (Fig. 3D) . Treatment with an independent inhibitor of GSK-3 (LiCl) similarly protected TAZ from degradation in YAP-inducible NIH3T3 cells (Fig. 3E ). Since GSK-3 is reported to phosphorylate and degrade TAZ (33), we hypothesized that YAP induction might increase GSK-3 activity, resulting in TAZ phosphorylation and subsequent degradation. To test this, we assessed the relative abundance of GSK-3 phosphorylation on serine residues 21 and 9 for GSK-3␣ and ␤, respectively, following YAP induction as an indicator of GSK-3 activity (reviewed in Ref. 44) . Surprisingly, no significant change in the relative abundance of phospho-GSK-3 was observed following YAP induction for up to 24 h (Fig. 3F) . These results indicate that while YAP overexpression does not directly modulate GSK-3 activity, active GSK-3␣/␤ is still required for YAP-induced TAZ degradation.
To investigate whether YAP-induced TAZ degradation is conserved in human cells, HeLa and D645 human cell lines were generated that can be induced to express three of the eight isoforms of human YAP (hYAP): hYAP1-1␣, hYAP1-1␤, and hYAP1-2␣ (36) . Consistent with mouse cell data, induction of hYAP1-2␣, which is most similar to mYAP (90% similarity; 84% identity) led to a significant reduction in TAZ abundance in the two cell lines (Fig. 4A ). Induction of hYAP1-1␣, which differs from hYAP1-2␣ by the absence of YAP's second WW domain, led to a reduction in TAZ comparable to hYAP1-2␣ ( Fig. 4A) . Surprisingly, induction of hYAP1-1␤, which harbors an insertion of four amino acids within the leucine zipper motif of YAP TAD, was significantly less effective at inducing TAZ depletion compared with hYAP1-1␣ hYAP1-2␣, despite being expressed at an even higher level (Fig. 4A) . These results indicate that isoform specific differences affect the ability of YAP to degrade TAZ.
Despite YAP being a bona fide oncogene, overexpression of hYAP isoforms can result in apoptotic cell death in human cells (45) . Since TAZ is reported to promote cell proliferation and protect cells from apoptosis (8) , we hypothesized that in human cells YAP-induced TAZ depletion may inhibit cell growth and cause loss of cell viability. To examine this, TAZ was knocked down in HeLa and D645 cells using two independent shRNAs (Fig. 4B) . Strikingly, TAZ depletion in both cell lines drastically reduced cell number after 7 days as evaluated by clonogenic assay (Fig. 4C ). To determine whether the reduced number of cells following TAZ knockdown was a result of increased cell death, shRNA infected HeLa and D645 cells were treated with the pan-caspase inhibitor Q-VD immediately following selection to block apoptosis (46) . Treatment with Q-VD markedly increased the number of adherent TAZ knockdown cells at 6 days post-infection, while having minimal effect on Con cells (Fig. 4, D and E) . Together, these results indicate that TAZ depletion induces cell growth inhibition and apoptotic cell death in these cells and likely contributes to previously reported cell death induced by YAP overexpression.
Discussion
The novel results presented here unequivocally show that YAP abundance regulates TAZ protein accumulation in human and murine cells. Using an inducible overexpression system that afforded data that was not confounded by selection bias we demonstrated that YAP-induced TAZ degradation occurs rapidly, within 8 -16 h of YAP expression, and it is a direct consequence of YAP abundance on TAZ protein.
Interestingly this phenomenon was uni-directional since modulating TAZ expression levels did not affect YAP protein abundance, and this is reflected in the differences in stability of the two proteins: TAZ is constantly turned over while YAP is relatively stable. Consistent with earlier reports in HeLa and MCF10A cells (32) our data showed a significant decrease in TAZ but not YAP abundance upon treatment with an inhibitor of protein synthesis. Moreover inhibition of proteasomal degradation significantly increased TAZ but not YAP abundance similar to that shown for MCF10A and BT549 cells (32) . Indeed in U2OS cells it was shown that YAP has a half-life approximately twice that of TAZ (47) . The rapid turnover of TAZ relative to YAP affords more avenues for modulation by other factors/pathways to influence its accumulation within cells. Indeed, the uni-directional nature of YAP-TAZ regulation may simply reflect differences in the relative stabilities of the two proteins.
Proteasomal degradation of TAZ in the cytosol was shown to be the mechanism of TAZ depletion upon YAP induction, and this is consistent with the established mechanism of YAP/TAZ degradation (31, 32) .
Structure/function analyses revealed that YAP TAD and PDZ-binding motif, which is essential for nuclear localization (45, 48) , are indispensable for TAZ degradation. YAP-TEAD association was also implicated by the partial protection of TAZ degradation afforded by mutation of serine 79 (Ser-79) to alanine. Mutation of Ser-79 has been shown to significantly reduce interaction with TEAD factors, although not entirely (16) , which may explain why YAP-induced TAZ degradation was only partially blocked. These results suggest that YAP-induced TAZ degradation is a consequence of YAP-target gene transcription involving TEAD factors; however, these results do not exclude additional non-transcriptional mechanisms.
While Hsp90 inhibition successfully blocked YAP-induced TAZ degradation, there was reasonable concern regarding the specificity of targeting LATS 1/2 via inhibition of the broad acting Hsp90 chaperone. This concern is justified since partial knockdown of LATS 1 and 2 was insufficient to block YAPinduced TAZ degradation. Although not conclusive, this suggests that a Hsp90 substrate other than the LATS kinases mediates this effect. Subsequent investigation into the role of CK1␦/⑀ and GSK-3␣/␤ in TAZ degradation using inhibitors disclosed a role for GSK-3␣/␤, but not CK1␦/⑀ in YAP-induced TAZ degradation. The lack of a requirement for CK1␦/⑀ in this process adds support to our finding that LATS kinases are not likely involved. Based on current models of TAZ degradation, we would expect CK1␦/⑀ inhibition to block YAP-induced TAZ degradation if LATS was mediating this effect, however this was not observed.
Our data suggest a role for GSK-3␣/␤ in YAP-induced TAZ degradation. Interestingly, GSK-3 tyrosine (activating) intramolecular autophosphorylation is reportedly mediated by Hsp90 (49) . Thus a decrease in Hsp90-mediated GSK-3 activity, and not LATS 1/2 depletion could account for the effectiveness of the Hsp90 inhibitor 17-AAG, and relative ineffectiveness of the LATS shRNAs in preventing YAP-induced TAZ degradation. Importantly however, induction of YAP does not directly alter GSK-3␣/␤ activity based on its phosphorylation status. Therefore we hypothesize that YAP-induction initiates a different signaling event required for TAZ degradation, though what this is remains to be identified.
We considered the possibility that YAP might promote an association of TAZ with the ␤-catenin destruction complex (34, 35) . In this model ␤-catenin is directly ubiquitinated following GSK-3 phosphorylation and serves as a scaffold for TAZ association with ␤-TrCP/E3 ubiquitin-ligase (34) . Using a tandemubiquitinated binding entity (TUBE) assay in our system we have found that ␤-catenin is highly ubiquitinated following (1-1␣), hYAP1-1␤ (1-1␤), or hYAP1-2␣ (1-2␣) were treated with or without 4HT for 24 h as indicated before being harvested. B, wild-type HeLa and D645 cells were stably infected with lentiviruses bearing control (Con) or human TAZ-specific (KD1 and KD2) shRNAs. After selection with puromycin for 24 h cells were trypsinized and harvested. Cell lysates were separated by SDS-PAGE, transferred to membrane and immunoblotted for YAP, TAZ, and ␤-actin as indicated. Size markers are shown in kilodaltons. C, HeLa and D645 Con, KD1 and KD2 cells from B were counted and 5 ϫ 10 4 cells plated into 60-mm dishes and cultured for 7 days. Cells were then fixed with glutaraldehyde and stained using crystal violet. HeLa (D) and D645 (E) Con, KD1, and KD2 cells were prepared as in C except cells were plated in the presence (ϩ) or absence (Ϫ) of 20 M Q-VD and cultured for 6 days before capturing images. Scale bar represents 100 m. YAP induction (data not shown) suggesting TAZ association with ␤-catenin may be a possible mechanism leading to its degradation following YAP induction.
Here we show that cellular depletion of TAZ by YAP is conserved between mouse and human cells. This is a significant observation since YAP/TAZ dysregulation is a known oncogenic driver in many human cancers (reviewed in Refs. 23, 50) . Interestingly, differences in the effectiveness of TAZ depletion were observed between the human YAP isoforms examined. Specifically that disruption of the leucine zipper motif (also known as the coiled-coil motif) within the TAD of some isoforms significantly reduced YAP ability to promote TAZ degradation. This is consistent with data demonstrating the requirement for the TAD to promote TAZ degradation (Fig.  2C) . While a leucine zipper is not essential for transcription co-activation within the TAD since for example TAZ does not harbor one in its TAD, it is widely accepted that YAP co-activates transcription by recruiting members of the basal transcription machinery, but may also promote recruitment of other factor/s that are necessary to promote TAZ degradation.
The difference in signaling among the YAP eight known isoforms is an overlooked area of Hippo signaling. Our data demonstrate that different hYAP isoforms can have significantly varying effects on TAZ abundance, which may influence the biological outcome of YAP overexpression. For instance it may be that a YAP isoform that promotes TAZ degradation is less biologically potent or oncogenic compared with an isoform that does not since the effects of YAP and TAZ are overlapping and additive.
The observation that TAZ depletion in human cells restricts cell growth and causes apoptotic cell death is significant as it helps us to rationalize the reports of YAP overexpression resulting in apoptosis in some cells. While we do not dispute that YAP association with p73 can result in promotion of apoptosis (24 -27) , undoubtedly YAP-induced TAZ depletion may contribute to cell death. Notably, TAZ knockdown in murine cells had no obvious effect on cell survival (data not shown), suggesting that there are intrinsic differences in the requirement for TAZ in the mouse and human cell lines tested. Moreover, a cell that depends on TAZ for survival may die upon YAP overexpression as a consequence of the induced TAZ degradation.
The significance of these findings lies in the context of cancer and therapeutic YAP-targeting strategies. Targeting YAP alone may be insufficient to modulate the oncogenic effects of Hippo signaling since YAP and TAZ have overlapping functions and share common target genes (3). For example, to successfully block Hippo pathway-driven proliferation of cancer cells, direct targeting of TAZ, or a combinatorial approach targeting both YAP and TAZ may be more effective since our data suggest this would avoid compensatory increases in TAZ if only YAP was targeted. Furthermore, the ability of YAP to regulate TAZ abundance could explain, in part, how YAP and TAZ possess contradictory roles as both oncogenes and tumor suppressors. Perhaps when YAP is down-regulated or deleted, the resultant increase in TAZ abundance has an overall oncogenic effect. Similarly, for YAP to be oncogenic, the mechanism by which TAZ is degraded may need to be dysregulated to prevent TAZ loss that would otherwise compensate for increased YAP abun-dance/activity thereby resulting in a net increase in Hippo signaling.
This study has identified a novel regulatory mechanism that maintains Hippo signaling at constant levels under normal circumstances. Changes in YAP abundance/activity lead to compensatory changes in TAZ. Mechanistically it may be simpler to achieve this if the regulation was one-directional i.e. YAP affects TAZ abundance but not vice-versa. However, it is interesting to speculate that the phenomenon might reflect the biological potency or importance of the two proteins. As highlighted in this study, TAZ is more highly regulated than YAP. Thus it is conceivable that TAZ might be more potent than YAP and existing regulatory mechanisms restrict its detrimental accumulation in cells, which is reflected by its shorter halflife that places a higher energy demand on the cell. Future work should build on the results presented here to obtain a more complete understanding of the mechanism of TAZ degradation induced by YAP, specifically identifying the links between YAP expression, GSK-3 signaling, and TAZ degradation. 
